Table 2.
Comparison of qualitative variables between patients with lower and higher PFA.
| Clinicopathological variables | Group 1 (PFA <20.2 cm2, n = 151) | Group 2 (PFA ≥ 20.2 cm2, n = 152) | P | |
|---|---|---|---|---|
| Sex | Male | 91 (60.3%) | 113 (74.3%) | 0.009 |
| Female | 60 (39.7%) | 39 (25.7%) | ||
| Surgical procedure | Dixon | 134 (88.7%) | 139 (91.4%) | 0.593 |
| Miles | 15 (9.9%) | 10 (6.6%) | ||
| Hartmann | 2 (1.3%) | 3 (2%) | ||
| Combined resection | No | 143 (94.7%) | 146 (96.1%) | 0.576 |
| Yes | 8 (5.3%) | 6 (3.9%) | ||
| Stoma | No | 51 (33.8%) | 54 (35.5%) | 0.749 |
| Yes | 100 (66.2%) | 98 (64.5%) | ||
| Radical resection | No | 4 (2.6%) | 4 (2.6%) | 1.000 |
| Yes | 147 (97.4%) | 148 (97.4%) | ||
| Laparoscopic surgery | Open | 129 (85.4%) | 123 (80.9%) | 0.294 |
| Laparoscopic | 22 (14.6%) | 29 (19.1%) | ||
| History of other cancer | No | 147 (97.4%) | 150 (98.7%) | 0.448 |
| Yes | 4 (2.6%) | 2 (1.3%) | ||
| Family history of cancer | No | 137 (90.7%) | 136 (89.5%) | 0.715 |
| Yes | 14 (9.3%) | 16 (10.5%) | ||
| Diabetes | No | 133 (88.1%) | 138 (90.8%) | 0.443 |
| Yes | 18 (11.9%) | 14 (9.2%) | ||
| Hypertension | No | 99 (65.6%) | 100 (65.8%) | 0.967 |
| Yes | 52 (34.4%) | 52 (34.2%) | ||
| History of appendectomy | No | 131 (86.8%) | 139 (91.4%) | 0.190 |
| Yes | 20 (13.2%) | 13 (8.6%) | ||
| Concomitant polyp | No | 137 (90.7%) | 133 (87.5%) | 0.367 |
| Yes | 14 (9.3%) | 19 (12.5%) | ||
| Gross appearance | Ulcerative | 103 (68.2%) | 113 (74.3%) | 0.238 |
| Protruding | 48 (31.8%) | 39 (25.7%) | ||
| Differentiation | Moderate | 123 (81.5%) | 126 (82.9%) | 0.744 |
| Poor | 28 (18.5%) | 26 (17.1%) | ||
| Invasion depth (T stage) | 1 | 13 (8.6%) | 4 (2.6%) | 0.077 |
| 2 | 38 (25.2%) | 33 (21.7%) | ||
| 3 | 95 (62.9%) | 106 (69.7%) | ||
| 4 | 5 (3.3%) | 9 (5.9%) | ||
| Lymph node metastasis (N stage) | 0 | 94 (62.3%) | 72 (47.4%) | 0.029 |
| 1 | 35 (23.2%) | 53 (34.9%) | ||
| 2 | 22 (14.6%) | 27 (17.8%) | ||
| Distant metastasis (M stage) | No | 137 (90.7%) | 140 (92.1%) | 0.669 |
| Yes | 14 (9.3%) | 12 (7.9%) | ||
| TNM stage | 1 | 36 (23.8%) | 24 (15.8%) | 0.013 |
| 2 | 54 (35.8%) | 41 (27%) | ||
| 3 | 47 (31.1%) | 75 (49.3%) | ||
| 4 | 14 (9.3%) | 12 (7.9%) | ||
| BRAF | Wild | 146 (96.7%) | 151 (99.3%) | 0.121 |
| Mutant | 5 (3.3%) | 1 (0.7%) | ||
| KRAS | Wild | 82 (54.3%) | 88 (57.9%) | 0.529 |
| Mutant | 69 (45.7%) | 64 (42.1%) | ||
| Tumor deposit | No | 126 (83.4%) | 102 (67.1%) | 0.001 |
| Yes | 25 (16.6%) | 50 (32.9%) | ||
| Vascular invasion | No | 130 (86.1%) | 122 (80.3%) | 0.175 |
| Yes | 21 (13.9%) | 30 (19.7%) | ||
| Perineural invasion | No | 124 (82.1%) | 123 (80.9%) | 0.788 |
| Yes | 27 (17.9%) | 29 (19.1%) | ||
| Circumferential resection margin | Negative | 147 (97.4%) | 148 (97.4%) | 1.000 |
| Positive | 4 (2.6%) | 4 (2.6%) | ||
| Distal resection margin | Negative | 150 (99.3%) | 150 (98.7%) | 1.000 |
| Positive | 1 (0.7%) | 2 (1.3%) | ||
| Postoperative chemotherapy | No | 43 (28.5%) | 44 (28.9%) | 0.928 |
| Yes | 108 (71.5%) | 108 (71.1%) | ||
| Postoperative radiation | No | 117 (77.5%) | 123 (80.9%) | 0.461 |
| Yes | 34 (22.5%) | 29 (19.1%) | ||